Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
The BMT data book
| The BMT data book |
| Edizione | [2nd ed. /] |
| Pubbl/distr/stampa | Cambridge ; ; New York, : Cambridge University Press, 2009 |
| Descrizione fisica | 1 online resource (xvi, 526 pages) : digital, PDF file(s) |
| Disciplina | 617.4/40592 |
| Altri autori (Persone) |
MunkerReinhold
LazarusHillard M AtkinsonKerry |
| Soggetto topico |
Bone marrow - Transplantation
Internal medicine |
| ISBN |
1-107-19285-4
0-511-51773-4 0-511-51511-1 0-511-51419-0 0-511-57552-1 0-511-51639-8 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Cover; Half-title; Title; Copyright; Contents; Contributors; Foreword; Preface; Acknowledgments; Section 1 Basic science; Section 2 Hematologic malignancies; Section 3 Solid tumors; Section 4 Nonmalignant disorders; Section 5 Practical aspects and procedures; Section 6 Complications; Section 7 The BMT/SCT pharmacopoeia; Section 8 HLA-testing and laboratorymedicine; Appendix; Index |
| Record Nr. | UNINA-9910811297003321 |
| Cambridge ; ; New York, : Cambridge University Press, 2009 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Concise Guide to Hematology / / edited by Hillard M. Lazarus, Alvin H. Schmaier
| Concise Guide to Hematology / / edited by Hillard M. Lazarus, Alvin H. Schmaier |
| Edizione | [2nd ed. 2019.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2019 |
| Descrizione fisica | 1 online resource (539 pages) |
| Disciplina | 616.15 |
| Soggetto topico |
Hematology
Oncology Oncology |
| ISBN | 3-319-97873-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Introduction to Hematology -- Hematopoiesis -- Red Blood Cell Biochemistry and Physiology -- Anemia: Clinical Approach -- Iron Deficiency -- Vitamin-B12 (Cobalamin) and Folate Deficiency -- Sickle Cell Disease and the Hemoglobinopathies -- Congenital Hemolytic Anemias -- Acquired Hemolytic Anemias -- Physiology of Hemostasis -- Approach to the Bleeding Patient -- Congenital Bleeding Disorders -- Acquired Bleeding Disorders -- Platelet Function in Hemostasis and Inherited Disorders of Platelet Number and Function -- Acquired Thrombocytopenia -- Thrombosis -- Anticoagulants and Treatment of Venous Thromboembolism -- Antiplatelet Therapy in Cardiovascular Disease -- Physiological Roles of Leukocytes and Disorders -- Pediatric Hematology -- Bone Marrow Structure And Marrow Aspiration, Biopsy, And Collection For Therapeutic Intent Procedures -- Flow Cytometry in Hematology -- Genetics In Hematologic Disorders: Implications of Recurring Chromosome -- Understanding Molecular Testing In Patients Affected By Hematologic Disorders -- Chronic Myeloid Leukemia (CML) -- Myeloproliferative Neoplasms -- Myelodysplastic Syndromes (MDS) -- Acute Leukemia -- Classification of Lymphomas -- Clinical Evaluation and Management of Hodgkin Lymphoma -- Indolent Lymphomas -- Aggressive Lymphoma -- Clinical Evaluation and Management of Chronic Lymphocytic Leukemia -- Plasma Cell Disorders -- Neoplastic Hematologic Disorders In Children and Adolescents -- Transfusion Medicine -- Hematopoietic Cell Transplantation -- Infections in Hematology Patients. |
| Record Nr. | UNINA-9910337477703321 |
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2019 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Molecular Hematology
| Molecular Hematology |
| Autore | Provan Drew |
| Edizione | [5th ed.] |
| Pubbl/distr/stampa | Newark : , : John Wiley & Sons, Incorporated, , 2024 |
| Descrizione fisica | 1 online resource (445 pages) |
| Disciplina | 616.1/5 |
| Altri autori (Persone) | LazarusHillard M |
| ISBN |
1-394-18046-2
1-394-18048-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover -- Title Page -- Copyright Page -- Dedication Page -- Contents -- List of contributors -- Foreword -- Preface -- Chapter 1 Beginnings: the molecular pathology of hemoglobin -- Introduction -- Normal structure and function of hemoglobin and the globin genes -- The structure and function of hemoglobin -- The structure of the globin gene loci -- Transcription, processing, and translation of globin RNA -- The regulation of globin gene transcription -- The regulation of developmental globin switching -- Molecular pathology of the globin genes -- The thalassemias -- Rare mutations causing thalassemia -- β Thalassemia -- Rare forms of β thalassemia -- δβ Thalassemia and hereditary persistence of fetal hemoglobin (HPFH) -- The pathophysiology and clinical phenotypes of thalassemia -- The α thalassemias -- The β thalassemias -- Development of therapies -- Conclusion -- Further reading -- General background -- Hemoglobin genetics and structural variants -- Hemoglobin switching -- The β thalassemias -- The α thalassemias -- Evolutionary background of hemoglobin disorders -- Molecular basis of prevention and management of hemoglobin disorders -- Chapter 2 Stem cells -- Introduction -- Stem cell definitions and distinctions -- Hematopoietic stem cell concepts and their origin -- The cellular compartment model -- Models of lineage commitment -- Molecular regulation of hematopoiesis -- Cell-intrinsic regulators of hematopoiesis -- Cell-extrinsic regulators -- Components of the hematopoietic microenvironmental niche -- Trafficking of primitive hematopoietic cells -- Hematopoietic ontogeny -- Homing and engraftment of HSPCs following infusion -- Egress of HSCs from bone marrow under physiological conditions -- Manipulating hematopoietic stem cells for clinical use -- Mobilization of HSCs -- Isolating stem cells for manipulation.
HSC from induced pluripotent stem cells -- Functional analysis of HSCs -- Summary -- Further reading -- Regulation of hematopoiesis -- Hematopoietic stem cell niche -- Hematopoietic stem cell quiescence -- Isolation of hematopoietic stem cells -- Hematopoietic stem/progenitor cell expansion -- Hematopoietic stem cell engraftment -- Chapter 3 The genetics of acute myeloid leukemia -- Introduction -- AML with recurrent cytogenetic abnormalities -- Core-binding factor leukemias -- Acute promyelocytic leukemia -- KMT2A gene rearrangements (11q23) -- Other rare chromosomal translocations -- Numerical chromosomal abnormalities -- Molecular genetic aberrations not detectable by conventional cytogenetics -- Driver gene mutations -- NPM1 -- Activated signaling -- FLT3 -- c-KIT -- Myeloid transcription factors -- RUNX1 -- CEBPA -- Tumor suppressors -- TP53 -- WT1 -- BCOR -- Spliceosome genes -- Cohesin complex gene -- DNA methylation -- DNMT3A -- IDH1 and IDH2 -- EZH2 -- TET2 -- Chromatin modifiers -- ASXL1 -- KTM2A (formerly MLL) -- Germline predisposition -- AML therapies and MRD monitoring targeted by genetics -- Summary -- Further reading -- Genetics of AML -- Core-binding factor leukemias -- NPM1 -- Activated signaling -- Myeloid transcription factors (RUNX1, CEBPA) -- Tumor suppressors (BCOR, TP53) -- Spliceosome genes -- Cohesin complex genes -- DNA methylation (EHZ2, TET2, IDH1/IDH2, DNMT3A) -- Chromatin modifiers -- Germline predisposition -- AML therapies and MRD monitoring targeted by genetics -- Chapter 4 Molecular diagnostics and risk assessment in myeloid malignancies -- Introduction -- A disease continuum -- General methodology of cytogenetic analysis in hematologic malignancies -- Methods of detection -- Genetic and clinical consequences of chromosomal translocation -- Karyotypic evolution -- Clinical implications -- Treatment selection. Recurrent cytogenetic abnormalities in MDS -- Recurrent cytogenetic aberrations in AML -- Therapy-related chromosomal aberrations in AML post cytotoxic therapy -- Recurrently mutated genes in MDS -- Mutations in splicing factors -- Epigenetic regulators -- Histone modification -- DNA methylation -- Cohesin complex -- Transcription factors -- Cell signaling genes -- TP53 -- Recurrently mutated genes in AML -- Differences and similarities of the WHO classification 2022 and the ICC 2022 -- References -- Further reading -- Chapter 5 Molecular basis of acute lymphoblastic leukemia -- Introduction -- B-cell precursor acute lymphoblastic leukemia -- High hyperdiploid ALL -- Hypodiploid ALL -- Intrachromosomal amplification of chromosome 21 (iAMP21) -- ETV6::RUNX1 and ETV6::RUNX1-like ALL -- TCF3-rearranged ALL (TCF3::PBX1 and TCF3::HLF) -- KMT2A-rearranged ALL -- BCR::ABL1 (Ph+) and Ph-like ALL -- DUX4-rearranged ALL -- MEF2D-rearranged ALL -- ZNF384-rearranged leukemia -- PAX5-driven ALL (PAX5alt and PAX5 P80R) -- CDX2/UBTF ALL -- NUTM1-rearranged ALL -- IKZF1 N159Y -- Other subtypes of B-ALL -- T-cell precursor acute lymphoblastic leukemia (T-ALL) -- Early T-cell precursor (ETP) ALL, immature T-ALL, and BCL11B-activated leukemia -- TLX1 and TLX3-driven T-ALL -- TAL1- and class II basic helix-loop-helix (bHLH) factor-deregulated T-ALL -- Other subtypes of T-ALL -- Summary -- Further reading -- Chapter 6 Chronic myelogenous leukemia -- Introduction -- Epidemiology -- Clinical presentation and natural history -- Prognostic models -- Molecular biology -- BCR::ABL1 oncogene -- BCR::ABL1 kinase signaling pathways -- Therapy -- General -- Frontline CML therapy -- Selection of frontline TKI therapy -- Discontinuation of TKI therapy and TFR -- Which treatment endpoints/milestones are clinically relevant in CML? -- Monitoring response and resistance. Distinguishing CML failure due to toxicities/intolerance versus true resistance -- Management of TKI "Failure" due to side effects/intolerance -- Management of CML post-TKI resistance (true CML failure) -- Other therapies -- Pregnancy and CML -- Allogeneic hematopoietic stem cell transplantation -- Therapy of CML-AP and CML-BP -- Philadelphia chromosome-negative CML -- Summary -- Further reading -- Molecular biology of CML -- Prognostic factors and models -- Interferon-α -- Allogeneic hematopoietic stem cell transplantation -- Imatinib and other tyrosine kinase inhibitors -- Mechanisms of resistance to tyrosine kinase inhibitors -- Chapter 7 Myeloproliferative neoplasms -- Introduction -- JAK-STAT pathways with a focus on JAK2 -- The JAK2 V617F mutation in Philadelphia-negative MPNs -- JAK2 V617F: One mutation yet multiple phenotypes -- Other JAK2 mutations -- JAK2 exon12 mutations -- JAK2 variants and eosinophilia -- Germline JAK2 mutations -- JAK2 germline haplotype -- MPL mutations in ET and MF -- CALR mutations in ET and MF -- Other somatic mutations in ET, MF, and PV -- Reticulin deposition in MPN -- Chronic neutrophilic leukemia -- Chronic eosinophilic leukemia and other eosinophilic disorders -- Integration of molecular information into diagnostic algorithms and prognostication -- Conclusions -- Further reading -- Introduction -- The JAK2 V617F mutation in Philadelphia- negative MPNs -- JAK2 exon12 mutations -- JAK2 variants and eosinophilia -- Germline JAK2 mutations -- JAK2 germline haplotype -- MPL mutations in ET and MF -- CALR mutations in ET and MF -- Other somatic mutations in ET, ET, and ET -- Chronic neutrophilic leukemia -- Chronic eosinophilic leukemia and other eosinophilic disorders -- Integration of molecular information into diagnostic algorithms and prognostication -- Chapter 8 Lymphoma genetics -- Introduction -- Techniques. Burkitt lymphoma -- Diffuse large B-cell lymphoma, not otherwise specified -- Mantle cell lymphoma -- Follicular lymphoma -- Lymphoplasmacytic lymphoma -- Marginal zone lymphoma -- Chronic lymphocytic leukemia/small lymphocytic lymphoma -- Anaplastic large cell lymphoma -- Nodal T-follicular helper (TFH) cell lymphoma -- Peripheral T-cell lymphoma, not otherwise specified -- Conclusions -- Further reading -- Introduction -- Techniques -- Burkitt lymphoma -- Diffuse large B-celllymphoma -- Mantle cell lymphoma -- Follicular lymphoma -- Lymphoplasmacytic lymphoma -- Marginal zone lymphomas -- CLL/SLL -- Anaplastic large cell lymphoma -- Nodal T-follicularhelper (TFH) cell lymphoma -- Peripheral T-celllymphoma, not otherwise specified -- Chapter 9 Molecular basis of chronic lymphocytic leukemia -- Introduction and definition -- Epidemiology -- Genetic factors -- Environmental factors -- Molecular biology of CLL -- IGHV mutations status -- Chromosome abnormalities -- Somatic mutations -- MicroRNA changes -- Epigenetic factors -- B-cell receptor signaling pathway -- BCL2 family -- CLL microenvironment -- Impaired immunity in CLL -- Richter transformation -- Definition -- Morphology and immunophenotype -- Clonal relatedness between CLL and lymphoma -- Biology of Richter's DLBCL -- Conclusion -- Further reading -- Chapter 10 The molecular biology of multiple myeloma -- Introduction -- Normal plasma cell development -- Development of myeloma cell -- Hyperdiploidy/trisomies -- IgH translocations -- Cyclin D dysregulation -- Progression to multiple myeloma -- Del (13q) -- RAS abnormalities -- MYC signaling -- Aberrant NF-B signaling -- Deletion of 17p [del(17p)] including TP53 -- Chromosome 1q gain, amplification -- Del (1p32) -- Bone marrow microenvironment -- Classification and risk stratification of myeloma -- Conclusion -- Further reading. Chapter 11 The molecular basis of bone marrow failure syndromes and red cell enzymopathies. |
| Record Nr. | UNINA-9910877406603321 |
Provan Drew
|
||
| Newark : , : John Wiley & Sons, Incorporated, , 2024 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||